QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

Oragenics Stock Price, News & Analysis (NYSEAMERICAN:OGEN)

$3.60
+0.09 (+2.57%)
(As of 11/28/2023 ET)
Compare
Today's Range
$3.50
$3.60
50-Day Range
$2.94
$4.18
52-Week Range
$2.60
$12.54
Volume
2,359 shs
Average Volume
15,973 shs
Market Capitalization
$9.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

OGEN stock logo

About Oragenics Stock (NYSEAMERICAN:OGEN)

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

OGEN Stock Price History

OGEN Stock News Headlines

StockNews.com Begins Coverage on Oragenics (NYSEAMERICAN:OGEN)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Oragenics, Inc. (UAV.F)
Oragenics Issues Update to Shareholders
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Oragenics, Inc. Announces Private Placement
Oragenics, Inc. Regains Compliance with NYSE American
Oragenics, Inc. Receives NYSE American Notice
Oragenics, Inc. Announces New Chair
Oragenics Inc OGEN Stock Quote
See More Headlines
Receive OGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
11/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:OGEN
Employees
6
Year Founded
N/A

Profitability

Net Income
$-14,290,000.00
Pretax Margin
-26,700.00%

Debt

Sales & Book Value

Annual Sales
$130,000.00
Book Value
$5.64 per share

Miscellaneous

Free Float
1,937,000
Market Cap
$9.25 million
Optionable
Not Optionable
Beta
0.53
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report














OGEN Stock Analysis - Frequently Asked Questions

How have OGEN shares performed in 2023?

Oragenics' stock was trading at $0.1051 at the beginning of 2023. Since then, OGEN stock has increased by 3,323.2% and is now trading at $3.5978.
View the best growth stocks for 2023 here
.

Are investors shorting Oragenics?

Oragenics saw a decline in short interest in the month of October. As of October 31st, there was short interest totaling 52,400 shares, a decline of 25.9% from the October 15th total of 70,700 shares. Based on an average trading volume of 17,400 shares, the short-interest ratio is presently 3.0 days. Currently, 2.5% of the shares of the stock are short sold.
View Oragenics' Short Interest
.

How were Oragenics' earnings last quarter?

Oragenics, Inc. (NYSEAMERICAN:OGEN) released its earnings results on Thursday, November, 9th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.01 million for the quarter.

When did Oragenics' stock split?

Oragenics's stock reverse split on the morning of Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Oragenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Imunon (CLSN), Jaguar Health (JAGX), Biocept (BIOC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Amarin (AMRN), Heat Biologics (HTBX), Idera Pharmaceuticals (IDRA) and Achieve Life Sciences (ACHV).

How do I buy shares of Oragenics?

Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:OGEN) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -